{
    "organizations": [],
    "uuid": "19bc144ab56a5fc672cbcdcb8187b74d5d5c0e65",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ablynx-completes-patient-recruitme/brief-ablynx-completes-patient-recruitment-in-phase-iib-respire-study-of-alx-0171-idUSFWN1S7013",
    "ord_in_thread": 0,
    "title": "BRIEF-Ablynx Completes Patient Recruitment In Phase IIb Respire Study Of ALX-0171",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - ABLYNX NV:\n* ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIB RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171\n* DATA FROM THIS PHASE IIB STUDY ARE EXPECTED TO BE REPORTED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-30T13:10:00.000+03:00",
    "crawled": "2018-05-01T19:46:31.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ablynx",
        "nv",
        "ablynx",
        "completes",
        "patient",
        "recruitment",
        "phase",
        "iib",
        "respire",
        "study",
        "inhaled",
        "nanobody",
        "data",
        "phase",
        "iib",
        "study",
        "expected",
        "reported",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}